Post‐chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study
Authors:
- 18 November 2016
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 114 (8) , 992-996
Abstract
Background and Objectives: To identify predictive preoperative factors of the presence of teratoma in retroperitoneal lymph node dissection specimens.Methods: We performed a 20 years multicenter retrospective analysis of all patients who underwent retroperitoneal lymph node dissection for residual masses after chemotherapy (PC‐RPLND). Patients had undergone PC‐RPLND after chemotherapy for advanced testicular cancer. The histologic components of the primary tumor were compared with those of the residual masses using logistic regression.Results: A total of 469 NSGCT patients underwent PC‐RPLND (complete data available for 211). By PC‐RPLND, necrosis was found in 84 cases, teratoma in 102 cases, and viable tumor in 25 cases. The univariate and multivariate analyses showed that teratoma (P = 0.001 and P = 0.002, respectively) and yolk sac tumor (P = 0.009 and P = 0.035, respectively) in orchiectomy specimens were statistically significant predictors of the presence of teratoma in retroperitoneal lymph nodes.Conclusions: PC‐RPLND is the standard treatment for any supracentimetric residual lesion. This procedure is associated with a high morbidity, and almost half patients are overtreated. The presence of teratoma and yolk sac tumor in the orchiectomy specimen were independent significant predictors of teratoma in retroperitoneal masses. J. Surg. Oncol. 2016;114:992–996.Keywords
This publication has 21 references indexed in Scilit:
- Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancerAnnals of Oncology, 2012
- Contemporary Management of Postchemotherapy Testis CancerEuropean Urology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell TumorsJournal of Clinical Oncology, 2007
- A comprehensive systematic review of testicular germ cell tumor surveillanceCritical Reviews in Oncology/Hematology, 2007
- Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual TeratomaJournal of Clinical Oncology, 2007
- Predicting Retroperitoneal Histology in Postchemotherapy Testicular Germ Cell Cancer: A Model Update and Multicentre Validation with More Than 1000 PatientsEuropean Urology, 2007
- Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node DissectionJournal of Urology, 2006
- Prediction of Necrosis After Chemotherapy of Advanced Germ Cell Tumors: Results of a Prospective Multicenter Trial of the German Testicular Cancer Study GroupJournal of Urology, 2004
- Teratoma in the Orchiectomy Specimen and Volume of Metastasis are Predictors of Retroperitoneal Teratoma in Post-Chemotherapy Nonseminomatous Testis CancerJournal of Urology, 2002